Levofloxacina Bruschettini (Levofloxacin Hemihydrate)

Levofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. By blocking these enzymes, the drug prevents bacterial cells from multiplying, leading to rapid bacterial death and resolution of the infection in the ocular tissues.

The dosage and frequency of Levofloxacina Bruschettini are determined by the prescribing clinician based on the specific infection, severity, and patient factors. The prescriber will provide the exact regimen on the prescription label.

Safety data for ocular levofloxacin in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Levofloxacina Bruschettini belongs to the fluoroquinolone class, offering broad‑spectrum coverage against Gram‑negative and some Gram‑positive ocular pathogens. Compared with older agents such as ciprofloxacin or ofloxacin, levofloxacin often provides higher potency and a lower risk of resistance, though choice depends on local susceptibility patterns and clinician preference.

Store the product at room temperature, preferably below 25 °C, in its original packaging. Protect it from direct light and moisture to maintain stability. Do not freeze the solution.

The medication is applied as eye drops. The prescribed number of drops is placed into the affected eye(s) according to the dosing schedule provided by the prescriber, typically after washing hands and avoiding contact between the dropper tip and the eye or any surface.

Serious risks include severe allergic reactions such as anaphylaxis, worsening of corneal ulcers, tendon rupture (especially with systemic exposure), and rare but life‑threatening skin reactions like Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience any of these symptoms.

Individuals with a known hypersensitivity to levofloxacin, other fluoroquinolones, or any component of the formulation should avoid this product. It is also contraindicated in patients where the prescriber determines that the risks outweigh the benefits, such as certain pregnant or breastfeeding patients without a clear indication.